These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 33204076)

  • 21. Severe community-acquired pneumonia in general medical wards: outcomes and impact of initial antibiotic selection.
    Wongsurakiat P; Chitwarakorn N
    BMC Pulm Med; 2019 Oct; 19(1):179. PubMed ID: 31619219
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Corticosteroids in Patients Hospitalized With Community-Acquired Pneumonia: Systematic Review and Individual Patient Data Metaanalysis.
    Briel M; Spoorenberg SMC; Snijders D; Torres A; Fernandez-Serrano S; Meduri GU; Gabarrús A; Blum CA; Confalonieri M; Kasenda B; Siemieniuk RAC; Boersma W; Bos WJW; Christ-Crain M; ; ;
    Clin Infect Dis; 2018 Jan; 66(3):346-354. PubMed ID: 29020323
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Sphingosine-1-phosphate as an indicator for deciding the use of adjuvant corticosteroids therapy in community-acquired pneumonia (sphingosine-1-phosphate and pneumonia trial): Study protocol for a randomized, placebo-controlled trial.
    Hsu SC; Huang WC; Liu CT; Hsu YP; Chang JH; Huang SK; Hsu CW
    Medicine (Baltimore); 2019 Sep; 98(38):e17278. PubMed ID: 31568009
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy and safety of trimodulin, a novel polyclonal antibody preparation, in patients with severe community-acquired pneumonia: a randomized, placebo-controlled, double-blind, multicenter, phase II trial (CIGMA study).
    Welte T; Dellinger RP; Ebelt H; Ferrer M; Opal SM; Singer M; Vincent JL; Werdan K; Martin-Loeches I; Almirall J; Artigas A; Ignacio Ayestarán J; Nuding S; Ferrer R; Sirgo Rodríguez G; Shankar-Hari M; Álvarez-Lerma F; Riessen R; Sirvent JM; Kluge S; Zacharowski K; Bonastre Mora J; Lapp H; Wöbker G; Achtzehn U; Brealey D; Kempa A; Sánchez García M; Brederlau J; Kochanek M; Reschreiter HP; Wise MP; Belohradsky BH; Bobenhausen I; Dälken B; Dubovy P; Langohr P; Mayer M; Schüttrumpf J; Wartenberg-Demand A; Wippermann U; Wolf D; Torres A
    Intensive Care Med; 2018 Apr; 44(4):438-448. PubMed ID: 29632995
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparative Efficacy of Chinese Herbal Injections for Septic Shock: A Bayesian Network Meta-Analysis of Randomized Controlled Trials.
    Huang P; Chen Y; Zhang H; Chen B; Zhao S; Feng Y; Lei S; Wu Q
    Front Pharmacol; 2022; 13():850221. PubMed ID: 35462931
    [No Abstract]   [Full Text] [Related]  

  • 26. CAL02, a novel antitoxin liposomal agent, in severe pneumococcal pneumonia: a first-in-human, double-blind, placebo-controlled, randomised trial.
    Laterre PF; Colin G; Dequin PF; Dugernier T; Boulain T; Azeredo da Silveira S; Lajaunias F; Perez A; François B
    Lancet Infect Dis; 2019 Jun; 19(6):620-630. PubMed ID: 31056427
    [TBL] [Abstract][Full Text] [Related]  

  • 27. "Efficacy and safety of the Qiguiyin formula in severe pneumonia: study protocol for a randomized, double-blind, placebo-controlled clinical trial".
    Huang P; Guo Y; Zhao J; Li B; Wu Y; Liu Q
    J Tradit Chin Med; 2020 Apr; 40(2):317-323. PubMed ID: 32242398
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Oral PSORI-CM01, a Chinese herbal formula, plus topical sequential therapy for moderate-to-severe psoriasis vulgaris: pilot study for a double-blind, randomized, placebo-controlled trial.
    Yao DN; Lu CJ; Wen ZH; Yan YH; Xuan ML; Li XY; Li G; He ZH; Xie XL; Deng JW; Guo XF; Ou AH
    Trials; 2016 Mar; 17(1):140. PubMed ID: 26983642
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy and Safety of Xuebijing Injection Combined With Ulinastatin as Adjunctive Therapy on Sepsis: A Systematic Review and Meta-Analysis.
    Chen G; Gao Y; Jiang Y; Yang F; Li S; Tan D; Ma Q
    Front Pharmacol; 2018; 9():743. PubMed ID: 30087610
    [No Abstract]   [Full Text] [Related]  

  • 30. Treatment with macrolides and glucocorticosteroids in severe community-acquired pneumonia: A post-hoc exploratory analysis of a randomized controlled trial.
    Ceccato A; Cilloniz C; Ranzani OT; Menendez R; Agusti C; Gabarrus A; Ferrer M; Sibila O; Niederman MS; Torres A
    PLoS One; 2017; 12(6):e0178022. PubMed ID: 28617807
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The current evidence for the treatment of sepsis with Xuebijing injection: Bioactive constituents, findings of clinical studies and potential mechanisms.
    Li C; Wang P; Li M; Zheng R; Chen S; Liu S; Feng Z; Yao Y; Shang H
    J Ethnopharmacol; 2021 Jan; 265():113301. PubMed ID: 32860891
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy and significance of various scores for pneumonia severity in the management of patients with community-acquired pneumonia in China.
    Yang Y; Xu F; Shi LY; Diao R; Cheng YS; Chen XY; Jing JY; Wang XD; Shen HH
    Chin Med J (Engl); 2012 Feb; 125(4):639-45. PubMed ID: 22490488
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Systemic corticosteroids for community-acquired pneumonia: reasons for use and lack of benefit on outcome.
    Polverino E; Cillóniz C; Dambrava P; Gabarrús A; Ferrer M; Agustí C; Prina E; Montull B; Menendez R; Niederman MS; Torres A
    Respirology; 2013 Feb; 18(2):263-71. PubMed ID: 23134361
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy of corticosteroids in community-acquired pneumonia: a randomized double-blinded clinical trial.
    Snijders D; Daniels JM; de Graaff CS; van der Werf TS; Boersma WG
    Am J Respir Crit Care Med; 2010 May; 181(9):975-82. PubMed ID: 20133929
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Corticosteroid therapy for severe community-acquired pneumonia: a meta-analysis.
    Cheng M; Pan ZY; Yang J; Gao YD
    Respir Care; 2014 Apr; 59(4):557-63. PubMed ID: 24046464
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Mortality prediction in community-acquired pneumonia requiring mechanical ventilation; values of pneumonia and intensive care unit severity scores.
    Aydoğdu M; Ozyilmaz E; Aksoy H; Gürsel G; Ekim N
    Tuberk Toraks; 2010; 58(1):25-34. PubMed ID: 20517726
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Why mortality is increased in health-care-associated pneumonia: lessons from pneumococcal bacteremic pneumonia.
    Rello J; Luján M; Gallego M; Vallés J; Belmonte Y; Fontanals D; Diaz E; Lisboa T;
    Chest; 2010 May; 137(5):1138-44. PubMed ID: 19952058
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy and safety of moxifloxacin in community acquired pneumonia: a prospective, multicenter, observational study (CAPRIVI).
    Kuzman I; Bezlepko A; Kondova Topuzovska I; Rókusz L; Iudina L; Marschall HP; Petri T
    BMC Pulm Med; 2014 Jun; 14():105. PubMed ID: 24975809
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Disease burden of pneumonia in Korean adults aged over 50 years stratified by age and underlying diseases.
    Lee JY; Yoo CG; Kim HJ; Jung KS; Yoo KH
    Korean J Intern Med; 2014 Nov; 29(6):764-73. PubMed ID: 25378975
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Safety and efficacy of CURB65-guided antibiotic therapy in community-acquired pneumonia.
    Chalmers JD; Singanayagam A; Akram AR; Choudhury G; Mandal P; Hill AT
    J Antimicrob Chemother; 2011 Feb; 66(2):416-23. PubMed ID: 21081545
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.